Urinary Exosomal miR-193a Can Be a Potential Biomarker for the Diagnosis of Primary Focal Segmental Glomerulosclerosis in Children.
Urinary Exosomal miR-193a Can Be a Potential Biomarker for the Diagnosis of Primary Focal Segmental Glomerulosclerosis in Children.
复制标题
尿液外泌体 miR-193a 可以成为诊断儿童原发性局灶节段性肾小球硬化症的潜在生物标志物
DOI：
10.1155/2017/7298160
复制
发表时间：
2017
影响因子：
--
通讯作者：
Zhang Y
中科院分区：
文献类型：
--
作者：
Huang Z;Zhang Y;Zhou J;Zhang Y
背景在原发性局灶节段性肾小球硬化症（FSGS）中检测到miR-193 a的肾小球上调，但在其他肾小球疾病中未检测到。我们的目的是从患有原发性FSGS的儿童的尿液中分离外泌体，并评估尿液外泌体miR-193 a对原发性FSGS的诊断潜力。方法.收集原发性FSGS（n = 8）和微小病变病（MCD，n = 5）儿童的第一次晨尿样本。通过电子显微镜和蛋白质印迹证实分离的尿外泌体。提取尿液外泌体microRNA，并通过实时PCR定量外泌体miR-193 a的表达水平。通过ROC分析评价尿外泌体miR-193 a水平对原发性FSGS的诊断价值。结果分离的囊泡与外来体定性相容。原发性FSGS患儿尿外泌体miR-193 a水平显著高于MCD患儿。此外，使用尿外泌体miR-193 a诊断原发性FSGS的ROC下面积为0.85。结论.与MCD患者相比，观察到原发性FSGS患者的尿外泌体miR-193 a水平显著增加。这项研究表明，尿外泌体miR-193 a可能是诊断原发性FSGS的新的非侵入性生物标志物。
Background. Glomerular upregulation of miR-193a has been detected in primary focal segmental glomerulosclerosis (FSGS) but not in other glomerular diseases. We aimed to isolate exosomes from urine of children with primary FSGS and to assess the diagnostic potential of urinary exosomal miR-193a for primary FSGS. Methods. The first morning urine samples were collected from children with primary FSGS (n = 8) and minimal change disease (MCD, n = 5). Isolated urinary exosomes were confirmed by electron microscopy and Western blotting. Urinary exosomal microRNA was extracted, and the expression levels of exosomal miR-193a were quantified by real-time PCR. The diagnosis value of urinary exosomal miR-193a levels for primary FSGS was evaluated by ROC analysis. Results. The isolated vesicles were qualitatively compatible with exosomes. The levels of urinary exosomal miR-193a were significantly higher in children with primary FSGS than those in children with MCD. Moreover, the area under the ROC for the diagnosis of primary FSGS using urinary exosomal miR-193a was 0.85. Conclusions. A significant increase in the levels of urinary exosomal miR-193a in primary FSGS patients compared to those in MCD ones was observed. This study suggests that urinary exosomal miR-193a may be a new noninvasive biomarker for the diagnosis of primary FSGS.